Overview

A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Rosuvastatin in Comparison to Each Component Administered Alone in Patients With Essential Hypertension and Dyslipidemia

Status:
Completed

Trial end date:
2015-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of combination of Fimasartan/Rosuvastatin in comparison to each component administered alone in patients with essential hypertension and dyslipidemia.

Phase:

Phase 3

Details

Lead Sponsor:

Boryung Pharmaceutical Co., Ltd

Treatments:

Rosuvastatin Calcium